drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Off-the-shelf allogeneic CD19-directed chimeric antigen receptor natural killer (CAR-NK) cell therapy designed to deplete CD19+ B-lineage cells to reduce pathogenic autoantibodies.
nci_thesaurus_concept_id
C181804
nci_thesaurus_preferred_term
Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019
nci_thesaurus_definition
A preparation of off-the-shelf (OTS), allogeneic and ex vivo expanded natural killer cells (NKs) that are engineered to express membrane-bound IL-15 (mbIL15) and a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 that is coupled to the co-stimulatory domain of OX40 (CD134), and to the zeta chain of the TCR/CD3 complex (CD3-zeta; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration of allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing NK cells NKX019, these cells specifically target and bind to tumor cells expressing CD19. This induces secretion of pro-inflammatory cytokines and results in the lysis of CD19-expressing tumor cells. IL-15 is a pro-survival cytokine that potentiates the immune response against tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Off-the-shelf allogeneic NK cells engineered with a CD19-targeted CAR containing OX40 and CD3ΞΆ signaling domains and membrane-bound IL-15. Upon binding CD19 on B-lineage cells, the CAR-NK cells are activated to release cytotoxic mediators and pro-inflammatory cytokines, leading to depletion of CD19+ B cells and reduction of pathogenic autoantibodies.
drug_name
NKX019
nct_id_drug_ref
NCT06557265